Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

Lindsay C. Spender, G. John Ferguson, Gareth D. Hughes, Barry R. Davies, Frederick W. Goldberg, Blanca Herrera, Richard G. Taylor, Lauren Strathearn, Owen J. Sansom, Simon T. Barry, Gareth Inman (Lead / Corresponding author)

Research output: Contribution to journalArticle

2 Citations (Scopus)
138 Downloads (Pure)

Abstract

The transforming growth factor β (TGF β) superfamily includes TGF β, activins, inhibins, and bone morphogenetic proteins (BMPs). These extracellular ligands have essential roles in normal tissue homeostasis by coordinately regulating cell proliferation, differentiation, and migration. Aberrant signaling of superfamily members, however, is associated with fibrosis as well as tumorigenesis, cancer progression, metastasis, and drug-resistance mechanisms in a variety of cancer subtypes. Given their involvement in human disease, the identification of novel selective inhibitors of TGF β superfamily receptors is an attractive therapeutic approach. Seven mammalian type 1 receptors have been identified that have context-specific roles depending on the ligand and the complex formation with the type 2 receptor. Here, we characterize the biologic effects of two transforming growth factor β receptor 1 (TGFBR1) kinase inhibitors designed to target TGF β signaling. AZ12601011 [2-(2-pyridinyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine]; structure previously undisclosed] and AZ12799734 [4-({4-[(2,6-dimethyl-3-pyridinyl)oxy]-2-pyridinyl}amino)benzenesulfonamide] (IC 50 = 18 and 47 nM, respectively) were more effective inhibitors of TGF β-induced reporter activity than SB-431542 [4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide] (IC 50 = 84 nM) and LY2157299 [4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide monohydrate]] (galunisertib) (IC 50 = 380 nM). AZ12601011 inhibited phosphorylation of SMAD2 via the type 1 receptors activin A receptor type 1B (ALK4), TGFBR1, and activin A receptor type 1C (ALK7). AZ12799734, however, is a pan TGF/BMP inhibitor, inhibiting receptor-mediated phosphorylation of SMAD1 by activin A receptor type 1L, bone morphogenetic protein receptor type 1A, and bone morphogenetic protein receptor type 1B and phosphorylation of SMAD2 by ALK4, TGFBR1, and ALK7. AZ12601011 was highly effective at inhibiting basal and TGF β-induced migration of HaCaT keratinocytes and, furthermore, inhibited tumor growth and metastasis to the lungs in a 4T1 syngeneic orthotopic mammary tumor model. These inhibitors provide new reagents for investigating in vitro and in vivo pathogenic processes and the contribution of TGF β- and BMP-regulated signaling pathways to disease states.

Original languageEnglish
Pages (from-to)222-234
Number of pages13
JournalMolecular Pharmacology
Volume95
Issue number2
Early online date14 Jan 2019
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Transforming Growth Factors
Activin Receptors
LY-2157299
Bone Morphogenetic Proteins
Bone Morphogenetic Protein Receptors
Growth Factor Receptors
Phosphorylation
Neoplasm Metastasis
Ligands
Activins
Neoplasms
Forensic Anthropology
Inhibins
Keratinocytes
Drug Resistance
Cell Movement
Cell Differentiation
Carcinogenesis
Homeostasis
Fibrosis

Keywords

  • Activin Receptors, Type I/metabolism
  • Animals
  • Bone Morphogenetic Proteins/metabolism
  • Cell Line
  • Cell Proliferation/drug effects
  • DNA-Binding Proteins
  • Mice
  • NIH 3T3 Cells
  • Neoplasm Metastasis/pathology
  • Phosphorylation/drug effects
  • Protein Kinase Inhibitors/pharmacology
  • Receptor, Transforming Growth Factor-beta Type I/metabolism
  • Signal Transduction/drug effects
  • Smad2 Protein/metabolism

Cite this

Spender, Lindsay C. ; Ferguson, G. John ; Hughes, Gareth D. ; Davies, Barry R. ; Goldberg, Frederick W. ; Herrera, Blanca ; Taylor, Richard G. ; Strathearn, Lauren ; Sansom, Owen J. ; Barry, Simon T. ; Inman, Gareth. / Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors. In: Molecular Pharmacology. 2019 ; Vol. 95, No. 2. pp. 222-234.
@article{d762b2cca82d46dabc0e5e2bbfaf029f,
title = "Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.",
abstract = "The transforming growth factor β (TGF β) superfamily includes TGF β, activins, inhibins, and bone morphogenetic proteins (BMPs). These extracellular ligands have essential roles in normal tissue homeostasis by coordinately regulating cell proliferation, differentiation, and migration. Aberrant signaling of superfamily members, however, is associated with fibrosis as well as tumorigenesis, cancer progression, metastasis, and drug-resistance mechanisms in a variety of cancer subtypes. Given their involvement in human disease, the identification of novel selective inhibitors of TGF β superfamily receptors is an attractive therapeutic approach. Seven mammalian type 1 receptors have been identified that have context-specific roles depending on the ligand and the complex formation with the type 2 receptor. Here, we characterize the biologic effects of two transforming growth factor β receptor 1 (TGFBR1) kinase inhibitors designed to target TGF β signaling. AZ12601011 [2-(2-pyridinyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine]; structure previously undisclosed] and AZ12799734 [4-({4-[(2,6-dimethyl-3-pyridinyl)oxy]-2-pyridinyl}amino)benzenesulfonamide] (IC 50 = 18 and 47 nM, respectively) were more effective inhibitors of TGF β-induced reporter activity than SB-431542 [4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide] (IC 50 = 84 nM) and LY2157299 [4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide monohydrate]] (galunisertib) (IC 50 = 380 nM). AZ12601011 inhibited phosphorylation of SMAD2 via the type 1 receptors activin A receptor type 1B (ALK4), TGFBR1, and activin A receptor type 1C (ALK7). AZ12799734, however, is a pan TGF/BMP inhibitor, inhibiting receptor-mediated phosphorylation of SMAD1 by activin A receptor type 1L, bone morphogenetic protein receptor type 1A, and bone morphogenetic protein receptor type 1B and phosphorylation of SMAD2 by ALK4, TGFBR1, and ALK7. AZ12601011 was highly effective at inhibiting basal and TGF β-induced migration of HaCaT keratinocytes and, furthermore, inhibited tumor growth and metastasis to the lungs in a 4T1 syngeneic orthotopic mammary tumor model. These inhibitors provide new reagents for investigating in vitro and in vivo pathogenic processes and the contribution of TGF β- and BMP-regulated signaling pathways to disease states.",
keywords = "Activin Receptors, Type I/metabolism, Animals, Bone Morphogenetic Proteins/metabolism, Cell Line, Cell Proliferation/drug effects, DNA-Binding Proteins, Mice, NIH 3T3 Cells, Neoplasm Metastasis/pathology, Phosphorylation/drug effects, Protein Kinase Inhibitors/pharmacology, Receptor, Transforming Growth Factor-beta Type I/metabolism, Signal Transduction/drug effects, Smad2 Protein/metabolism",
author = "Spender, {Lindsay C.} and Ferguson, {G. John} and Hughes, {Gareth D.} and Davies, {Barry R.} and Goldberg, {Frederick W.} and Blanca Herrera and Taylor, {Richard G.} and Lauren Strathearn and Sansom, {Owen J.} and Barry, {Simon T.} and Gareth Inman",
year = "2019",
month = "2",
day = "1",
doi = "10.1124/mol.118.112946",
language = "English",
volume = "95",
pages = "222--234",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors. / Spender, Lindsay C.; Ferguson, G. John ; Hughes, Gareth D.; Davies, Barry R.; Goldberg, Frederick W.; Herrera, Blanca; Taylor, Richard G.; Strathearn, Lauren; Sansom, Owen J.; Barry, Simon T.; Inman, Gareth (Lead / Corresponding author).

In: Molecular Pharmacology, Vol. 95, No. 2, 01.02.2019, p. 222-234.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

AU - Spender, Lindsay C.

AU - Ferguson, G. John

AU - Hughes, Gareth D.

AU - Davies, Barry R.

AU - Goldberg, Frederick W.

AU - Herrera, Blanca

AU - Taylor, Richard G.

AU - Strathearn, Lauren

AU - Sansom, Owen J.

AU - Barry, Simon T.

AU - Inman, Gareth

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The transforming growth factor β (TGF β) superfamily includes TGF β, activins, inhibins, and bone morphogenetic proteins (BMPs). These extracellular ligands have essential roles in normal tissue homeostasis by coordinately regulating cell proliferation, differentiation, and migration. Aberrant signaling of superfamily members, however, is associated with fibrosis as well as tumorigenesis, cancer progression, metastasis, and drug-resistance mechanisms in a variety of cancer subtypes. Given their involvement in human disease, the identification of novel selective inhibitors of TGF β superfamily receptors is an attractive therapeutic approach. Seven mammalian type 1 receptors have been identified that have context-specific roles depending on the ligand and the complex formation with the type 2 receptor. Here, we characterize the biologic effects of two transforming growth factor β receptor 1 (TGFBR1) kinase inhibitors designed to target TGF β signaling. AZ12601011 [2-(2-pyridinyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine]; structure previously undisclosed] and AZ12799734 [4-({4-[(2,6-dimethyl-3-pyridinyl)oxy]-2-pyridinyl}amino)benzenesulfonamide] (IC 50 = 18 and 47 nM, respectively) were more effective inhibitors of TGF β-induced reporter activity than SB-431542 [4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide] (IC 50 = 84 nM) and LY2157299 [4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide monohydrate]] (galunisertib) (IC 50 = 380 nM). AZ12601011 inhibited phosphorylation of SMAD2 via the type 1 receptors activin A receptor type 1B (ALK4), TGFBR1, and activin A receptor type 1C (ALK7). AZ12799734, however, is a pan TGF/BMP inhibitor, inhibiting receptor-mediated phosphorylation of SMAD1 by activin A receptor type 1L, bone morphogenetic protein receptor type 1A, and bone morphogenetic protein receptor type 1B and phosphorylation of SMAD2 by ALK4, TGFBR1, and ALK7. AZ12601011 was highly effective at inhibiting basal and TGF β-induced migration of HaCaT keratinocytes and, furthermore, inhibited tumor growth and metastasis to the lungs in a 4T1 syngeneic orthotopic mammary tumor model. These inhibitors provide new reagents for investigating in vitro and in vivo pathogenic processes and the contribution of TGF β- and BMP-regulated signaling pathways to disease states.

AB - The transforming growth factor β (TGF β) superfamily includes TGF β, activins, inhibins, and bone morphogenetic proteins (BMPs). These extracellular ligands have essential roles in normal tissue homeostasis by coordinately regulating cell proliferation, differentiation, and migration. Aberrant signaling of superfamily members, however, is associated with fibrosis as well as tumorigenesis, cancer progression, metastasis, and drug-resistance mechanisms in a variety of cancer subtypes. Given their involvement in human disease, the identification of novel selective inhibitors of TGF β superfamily receptors is an attractive therapeutic approach. Seven mammalian type 1 receptors have been identified that have context-specific roles depending on the ligand and the complex formation with the type 2 receptor. Here, we characterize the biologic effects of two transforming growth factor β receptor 1 (TGFBR1) kinase inhibitors designed to target TGF β signaling. AZ12601011 [2-(2-pyridinyl)-4-(1H-pyrrolo[3,2-c]pyridin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine]; structure previously undisclosed] and AZ12799734 [4-({4-[(2,6-dimethyl-3-pyridinyl)oxy]-2-pyridinyl}amino)benzenesulfonamide] (IC 50 = 18 and 47 nM, respectively) were more effective inhibitors of TGF β-induced reporter activity than SB-431542 [4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide] (IC 50 = 84 nM) and LY2157299 [4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide monohydrate]] (galunisertib) (IC 50 = 380 nM). AZ12601011 inhibited phosphorylation of SMAD2 via the type 1 receptors activin A receptor type 1B (ALK4), TGFBR1, and activin A receptor type 1C (ALK7). AZ12799734, however, is a pan TGF/BMP inhibitor, inhibiting receptor-mediated phosphorylation of SMAD1 by activin A receptor type 1L, bone morphogenetic protein receptor type 1A, and bone morphogenetic protein receptor type 1B and phosphorylation of SMAD2 by ALK4, TGFBR1, and ALK7. AZ12601011 was highly effective at inhibiting basal and TGF β-induced migration of HaCaT keratinocytes and, furthermore, inhibited tumor growth and metastasis to the lungs in a 4T1 syngeneic orthotopic mammary tumor model. These inhibitors provide new reagents for investigating in vitro and in vivo pathogenic processes and the contribution of TGF β- and BMP-regulated signaling pathways to disease states.

KW - Activin Receptors, Type I/metabolism

KW - Animals

KW - Bone Morphogenetic Proteins/metabolism

KW - Cell Line

KW - Cell Proliferation/drug effects

KW - DNA-Binding Proteins

KW - Mice

KW - NIH 3T3 Cells

KW - Neoplasm Metastasis/pathology

KW - Phosphorylation/drug effects

KW - Protein Kinase Inhibitors/pharmacology

KW - Receptor, Transforming Growth Factor-beta Type I/metabolism

KW - Signal Transduction/drug effects

KW - Smad2 Protein/metabolism

UR - http://www.scopus.com/inward/record.url?scp=85059879858&partnerID=8YFLogxK

U2 - 10.1124/mol.118.112946

DO - 10.1124/mol.118.112946

M3 - Article

C2 - 30459156

VL - 95

SP - 222

EP - 234

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -